Management Recommendation
Continue antibiotics for a total of 10 days (5 more days), do not repeat the lumbar puncture given clinical improvement and negative cultures, and arrange close outpatient follow-up with repeat clinical assessment within 48 hours of discharge.
Rationale for Antibiotic Duration
Given the clinical scenario of presumed bacterial meningitis (bulging fontanelle with fever) that was treated empirically, the FDA labeling for cefotaxime provides clear guidance: antibiotic therapy should continue for a minimum of 48-72 hours after defervescence or evidence of bacterial eradication 1. Your patient is now afebrile after 5 days of treatment with clinical improvement and resolution of the bulging fontanelle.
However, the critical consideration is that you initiated meningitis-dose antibiotics based on clinical suspicion. While you couldn't confirm meningitis via LP, the combination of:
- Fever in a 3.5-month-old
- Bulging fontanelle (a concerning sign)
- Pharyngitis as the only identified focus
- Empiric meningitis treatment already started
...means you must treat this as possible meningitis until proven otherwise.
Duration Algorithm:
- For confirmed Group A streptococcal infections: minimum 10 days 1
- For neonatal meningitis (if confirmed): 14-21 days depending on organism 2
- For your case (presumed but unconfirmed meningitis with clinical improvement): 10 days total is reasonable given:
- Negative blood and urine cultures
- Clinical improvement by day 5
- Afebrile status
- Normal inflammatory markers (CRP 0.5)
- Age >1 month (lower risk than neonates)
Repeat Lumbar Puncture Decision
Do not repeat the LP in this case. The ESCMID guideline explicitly states that "the yield of repeated lumbar puncture is probably limited, and therefore routine repetition of lumbar puncture is not indicated" 3.
Repeat LP is indicated only when:
- Neurologic deterioration occurs
- Persistent fever despite appropriate antibiotics
- Clinical worsening
- Concern for complications (abscess, empyema, hydrocephalus)
Your patient has the opposite trajectory: clinical improvement, defervescence, and resolution of the bulging fontanelle. The unsuccessful initial LP, while unfortunate, does not mandate a repeat attempt when the clinical course is favorable.
Risk Stratification Context
Research shows that in well-appearing infants >1 month with fever, individualized decision-making regarding LP is acceptable when performed by experienced clinicians 4. Your patient had:
- Low-risk features: Normal vitals, no septic appearance, normal development, CRP 0.5, normal CBC except lymphocytosis (typical for viral processes)
- One concerning feature: Bulging fontanelle (which has now resolved)
- Negative cultures: Blood and urine both negative
The negative predictive value for serious bacterial infection is high in this context, especially with clinical improvement on therapy 5.
Monitoring and Follow-up
Before Discharge:
- Ensure complete resolution of bulging fontanelle
- Confirm sustained afebrile state (>24 hours)
- Normal feeding and activity level
- Parental education on warning signs
Outpatient Follow-up:
- 48-72 hours post-discharge: Clinical reassessment
- 4-6 weeks post-treatment: Hearing evaluation (even for presumed meningitis) 2
- Ongoing: Developmental monitoring
Red Flags for Return:
- Recurrent fever
- Lethargy or irritability
- Poor feeding
- Vomiting
- Bulging fontanelle recurrence
- Seizures
- Any neurologic changes
Common Pitfalls to Avoid
- Stopping antibiotics too early: The 48-72 hour rule applies AFTER defervescence, not from start of therapy 1
- Over-investigating with repeat LP: This exposes the infant to unnecessary risk without clear benefit when clinically improving 3
- Ignoring the pharyngitis: While it may explain the fever, the bulging fontanelle elevated this to presumed meningitis—treat accordingly
- Inadequate follow-up: Even with negative cultures, hearing assessment is warranted given the clinical presentation 2
Antibiotic Transition
Continue IV cefotaxime and ampicillin for the full 10-day course. Do not switch to oral antibiotics for presumed meningitis, even with clinical improvement. The FDA labeling and guidelines support completing parenteral therapy for CNS infections 1.